{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-029561","form_type":"8-K/A","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.876811+00:00","generated_at":"2026-06-01T02:26:27.727498+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Avalo amends 8K to restate AlmataBio 2023 financials; net loss up $153K","bullets":["Restated AlmataBio net loss for April 28–Dec 31, 2023 to $812K from $659K, a $153K increase.","R&D expense corrected upward by $135K to $663K; G&A expense up $18K to $149K.","Restatement had no cash flow impact; cash and equivalents remained $1.767M at Dec 31, 2023.","Previously issued financials for AlmataBio are superseded by this restated filing.","Acquisition of AlmataBio by Avalo closed on March 27, 2024; this is Amendment No. 2 to the original 8-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-029561","json":"https://secwatch.observer/filing/0001628280-24-029561.json","markdown":"https://secwatch.observer/filing/0001628280-24-029561.md","text":"https://secwatch.observer/filing/0001628280-24-029561.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024029561/0001628280-24-029561-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828024029561/avtx-20240327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:26:27.727498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}